Beryl Leirvaag
Stilling
Overingeniør, Mohn kreftforskningslaboratorium
Tilhørighet
- E-post
- beryl.leirvaag@uib.no
- Telefonnummer
- +47 55976444
- Besøksadresse
-
Haukeland universitetssykehus, Laboratoriebygget
5009 Bergen - Rom: 1417, etg. 1M Laboratoriebygget
- Postadresse
-
Postboks 7804
5020 Bergen
Beryl Leirvaag
Stilling
Overingeniør, Mohn kreftforskningslaboratorium
Tilhørighet
Publikasjoner
Vitenskapelig artikkel
- Nikolaienko, Oleksii; Eikesdal, Hans Petter; Berge, Elisabet Ognedal et al. (2023). Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development. (ekstern lenke)
- Yndestad, Synnøve; Engebrethsen, Christina; Herencia-Ropero, A. et al. (2023). Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer. (ekstern lenke)
- Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa et al. (2020). Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. (ekstern lenke)
- Knappskog, Stian; Leirvaag, Beryl; Gansmo, Liv Beathe et al. (2016). Prevalence of the CHEK2 R95* germline mutation. (ekstern lenke)
- Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan et al. (2015). Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. (ekstern lenke)
- Knappskog, Stian; Chrisanthar, Ranjan; Løkkevik, Erik et al. (2012). Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. (ekstern lenke)